# A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

> **NCT01385566** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 223 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous
- **BIOLOGICAL:** ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous
- **BIOLOGICAL:** ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal
- **BIOLOGICAL:** ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal
- **BIOLOGICAL:** Full Dose Intradermal Placebo
- **BIOLOGICAL:** Intradermal Placebo

## Key facts

- **NCT ID:** NCT01385566
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01385566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01385566, "A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01385566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*